Mobile

A double blinded, placebo controlled, pilot study to investigate the safety, tolerability, pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the investigational drug B...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-002522-23

A double blinded, placebo controlled, pilot study to investigate the safety, tolerability, pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the investigational drug BAY 1067197 in patients with chronic heart failure

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to investigate the safety and tolerability of a multiple dose 7 day once-daily treatment of BAY 1067197 versus a 7 day treatment of placebo in patients with chronic systolic heart failure, determined by the incidence and severity of adverse clinical events, new laboratory and electrocardiographic abnormalities and to investigate the pharmacokinetics of a 7 day treatment with BAY 1067197 in patients with chronic systolic heart failure

Critère d'inclusion

  • Chronic systolic heart failure

Liens